An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Loxtra Eye Drops Containing Ofloxacin (3 mg), Prednisolone (2 mg) and Tetrahydrozoline Hydrochloride (0.4 mg) in Subjects with Bacterial Conjunctivitis and Other Ocular Inflammatory Conditions

drug protocol number
LOX001
drug sponsor
Jamjoom Pharmaceuticals
drug study
Loxtra
drug trial site
King Khalid University Hospital (Riyadh)
drug status
Completed
drug phase